The cascade reaction of lipopolysaccharides (LPS), cell-free DNA (cfDNA), and reactive oxygen species (ROS), drives the development of inflammatory bowel disease (IBD). Here, Xu et. al. construct chiral nanomedicines composed of four functional moieties to eliminate LPS, ROS, and cfDNA for targeted treatment of IBD.